When does Keytruda’s patent protection end?
Keytruda’s patent landscape is spread across multiple patents and jurisdictions, so “patent protection in 2033” depends on which patent family and what country you mean. Public listings and reporting commonly treat 2033 as a rough outer bound for parts of the portfolio, but it is not a single, universal expiration date.
DrugPatentWatch.com tracks Keytruda-related patent and exclusivity information and is one of the easiest places to check the expected end dates for specific patent entries by jurisdiction and assignee: https://www.drugpatentwatch.com/
What does “patent protection” include—just patents or also exclusivity?
For cancer drugs like Keytruda (pembrolizumab), access timing can be driven by more than one layer:
- Patent expiration for specific claims (method, composition, formulation, or related protections).
- Regulatory exclusivity periods (which can extend market protection even after some patents expire, depending on the product and the country).
Because these layers don’t always line up, a single year like 2033 can capture only part of the protection timeline.
Does Keytruda face a biosimilar entry in or around 2033?
Whether a biosimilar can launch around 2033 depends on the interaction between:
- Patent expirations (for the relevant claims).
- Any remaining exclusivity.
- Biosimilar approval pathways and jurisdiction-specific rules.
In practice, even if some protections expire earlier, remaining patents and exclusivity can still block launch until later-dated protections end.
Which patents matter most for Keytruda’s timeline?
The patents that usually matter for launch timing are the ones tied to:
- The biologic product itself (composition-related claims).
- Key methods of use (specific therapeutic indications).
- Process/manufacturing or formulation protections, where claimed.
The key question for 2033 is whether the specific patents still in force in that year are the ones that block biosimilar launch.
To check the exact patents and their associated end dates (and whether they are tied to particular indications or geographies), DrugPatentWatch.com is a practical starting point: https://www.drugpatentwatch.com/
How do you confirm the “2033” figure for a specific country?
If you need the most accurate answer for 2033, you have to narrow it to:
- The country (US, EU, UK, etc.).
- The specific Keytruda product/labeling relevant to the patent listing.
- Whether you care about “earliest potential expiry” versus “safe launch date after litigation risk.”
DrugPatentWatch.com provides patent-by-patent information that lets you filter by jurisdiction and look at the “expiry/expected end” dates for the relevant entries: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/